| Literature DB >> 29046310 |
Madison Zuverink1, Joseph T Barbieri2.
Abstract
Select agents (SA) pose unique challenges for licensing vaccines and therapies. In the case of toxin-mediated diseases, HHS assigns guidelines for SA use, oversees vaccine and therapy development, and approves animal models and approaches to identify mechanisms for toxin neutralization. In this commentary, we discuss next-generation vaccines and therapies against ricin toxin and botulinum toxin, which are regulated SA toxins that utilize structure-based approaches for countermeasures to guide rapid response to future biothreats.Entities:
Keywords: RTA; RVEc; RiVax; antibodies; botulinum toxin; mass spectrometry; ricin
Mesh:
Substances:
Year: 2017 PMID: 29046310 PMCID: PMC5717179 DOI: 10.1128/CVI.00275-17
Source DB: PubMed Journal: Clin Vaccine Immunol ISSN: 1556-679X